Skip to main content

Press Releases and Ad-hoc Announcements

23 October 2025
PR: Heidelberg Pharma’s Lead ADC Candidate HDP-101 Granted Fast Track Designation by US FDA for the Treatment of Multiple Myeloma
PDF
09 October 2025
Heidelberg Pharma Reports on the First Nine Months of Financial Year 2025
PDF
06 October 2025
AH: Heidelberg Pharma AG Announces Updated Guidance
PDF
25 September 2025
PR: Heidelberg Pharma Advances to Cohort 9 in Phase I/IIa Trial of Lead ATAC Candidate HDP-101 in Multiple Myeloma
PDF
25 September 2025
PR: Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment
PDF
25 September 2025
AH: Heidelberg Pharma Significantly Reduces Operating Costs and Focuses on Lead ADC Candidate HDP-101 Due to Delayed Milestone Payment
PDF
04 September 2025
PR: Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2025
PDF
28 August 2025
AH: Heidelberg Pharma’s Partner Telix Pharmaceuticals Gives Regulatory Update for its Imaging Agent TLX250-CDx
PDF
10 July 2025
PR: Heidelberg Pharma Reports on First Half-Year 2025 and the Positive Course of Business
PDF
27 May 2025
PR: Heidelberg Pharma Announces First Patient Dosed in Phase I Study of Amanitin-based ADC Candidate HDP-102 for Non-Hodgkin Lymphoma
PDF
15 May 2025
PR: Heidelberg Pharma Reports on the Results of the Ordinary Annual General Meeting 2025 and New Supervisory Board
PDF
14 May 2025
PR: Heidelberg Pharma to Present Promising New Clinical Data on its Lead ATAC Candidate HDP-101 at EHA 2025
PDF
24 April 2025
PR: Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2025
PDF
26 March 2025
PR: Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025
PDF
21 March 2025
PR: Heidelberg Pharma announces financial figures and reports on successful business performance in 2024
PDF
13 March 2025
PR: Heidelberg Pharma Amends Royalty Financing with HealthCare Royalty
PDF
13 March 2025
AH: Heidelberg Pharma Amends Royalty Financing with HealthCare Royalty
PDF
13 January 2025
PR: Heidelberg Pharma Progresses into Cohort 7 in a Phase I/IIa Study with BCMA ATAC Candidate HDP-101 Targeting Multiple Myeloma
PDF
06 November 2024
PR: Heidelberg Pharma: Promising New Clinical Data on Lead ADC-Candidate HDP-101 to be Presented at ASH Annual Meeting 2024
PDF
24 October 2024
PR: Heidelberg Pharma to Participate in Leading Scientific and Financial Conferences in November 2024
PDF
10 October 2024
PR: Heidelberg Pharma AG: Interim Management Statement on the First Nine Months of 2024
PDF
01 October 2024
PR: Heidelberg Pharma: New Clinical Data on Lead ADC Candidate HDP-101 Presented at IMS 2024 Demonstrating Complete Remission in One Patient
PDF
01 October 2024
AH: Heidelberg Pharma AG Announces Updated Guidance
PDF
23 September 2024
PR: Heidelberg Pharma Announces New Clinical Data on Lead ATAC Candidate HDP-101 to be Presented at International Myeloma Society Annual Meeting 2024
PDF
11 July 2024
PR: Heidelberg Pharma Reports on First Half-Year 2024 and the Course of Business
PDF
21 June 2024
PR: Heidelberg Pharma reports on the results of the Annual General Meeting 2024
PDF
18 June 2024
AH: Heidelberg Pharma AG Announces Updated Guidance
PDF
23 May 2024
PR: Heidelberg Pharma to Participate and Present at Upcoming Leading Scientific Conferences in May and June 2024
PDF
25 April 2024
PR: Heidelberg Pharma AG: Interim Management Statement on the First Three Months of 2024
PDF
05 April 2024
PR: Heidelberg Pharma to host R&D Webinar following novel data presented at AACR
PDF